BTIG MedTech Conference: Unveiling Opportunities in Healthcare and Biotech

The BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, scheduled for February 11-12, 2025, in Snowbird, Utah, presents an excellent opportunity for investors to explore the resilient healthcare and biotech sectors. This annual event brings together over 75 corporate management teams, providing institutional investors with a unique platform to connect, network, and gain insights into the latest trends and innovations in the industry.

The conference, hosted by BTIG analysts such as David Larsen, Marie Thibault, Mark Massaro, Ryan Zimmerman, Sam Eiber, and Juliette Lafille, offers a comprehensive overview of the healthcare and biotech sectors. Attendees can expect in-depth analysis, expert insights, and valuable networking opportunities, all of which can help inform investment decisions.

One of the key highlights of the conference is the fireside chat titled "2025 Reimbursement and Regulatory Outlook Under the Trump Administration 2.0." This session, featuring Gabriel Bien-Willner, MD, PhD, Chief Medical Officer of Palmetto GBA and Medical Director of the MolDX (Molecular Diagnostic Services) Program, and Brian Carey, JD, Partner at Hogan Lovells US LLP, will provide attendees with a deeper understanding of the regulatory and reimbursement landscape. This information is crucial for investors looking to identify potential risks and opportunities within the industry.

The conference also offers investors the chance to meet with management teams from various companies, such as electroCore, Inc. (ECOR) and Delcath Systems, Inc. (DCTH). These one-on-one and hybrid group meetings provide valuable insights into companies' strategies, financial health, and growth prospects, enabling investors to make more informed decisions.

electroCore, Inc. (ECOR) is a commercial-stage bioelectronic medicine and wellness company focusing on non-invasive vagus nerve stimulation (nVNS) technology. The company's CEO, Dan Goldberger, will be hosting one-on-one meetings at the conference, giving investors the opportunity to learn more about electroCore's innovative technology and growth prospects.

Delcath Systems, Inc. (DCTH) is an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. The company's proprietary products, HEPZATO KIT and CHEMOSAT, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a percutaneous hepatic perfusion (PHP) procedure. Delcath's management team will be attending the conference, providing investors with an opportunity to learn more about the company's innovative technology and growth prospects.

By attending the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, investors can gain a better understanding of the healthcare and biotech sectors, identify potential risks and opportunities, and make more informed decisions aligned with their investment goals. The conference's focus on resilient sectors, diverse range of companies, and in-depth analysis make it an invaluable event for investors looking to manage risks and identify recovery opportunities in the healthcare and biotech industries.